X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (145) 145
male (109) 109
female (103) 103
oncology (94) 94
aged (87) 87
index medicus (86) 86
middle aged (86) 86
cancer (65) 65
adult (62) 62
chemotherapy (51) 51
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
gastroenterology & hepatology (37) 37
treatment outcome (36) 36
colorectal cancer (34) 34
gastric cancer (32) 32
stomach neoplasms - drug therapy (32) 32
medicine & public health (29) 29
stomach cancer (28) 28
aged, 80 and over (26) 26
care and treatment (26) 26
metastasis (26) 26
oxaliplatin (26) 26
animals (25) 25
prognosis (25) 25
stomach neoplasms - pathology (25) 25
survival (25) 25
analysis (24) 24
fluorouracil (24) 24
survival rate (24) 24
research (23) 23
5-fluorouracil (22) 22
cisplatin (22) 22
surgical oncology (22) 22
gastroenterology and hepatology (21) 21
japan (21) 21
trial (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
camptothecin - analogs & derivatives (20) 20
fluorouracil - administration & dosage (20) 20
therapy (20) 20
cancer research (19) 19
colorectal neoplasms - drug therapy (19) 19
disease-free survival (19) 19
cisplatin - administration & dosage (18) 18
clinical trials (18) 18
gastroenterology (18) 18
oncology, experimental (18) 18
original (18) 18
surgery (18) 18
tegafur - administration & dosage (18) 18
antimitotic agents (17) 17
antineoplastic agents (17) 17
drug combinations (17) 17
expression (17) 17
camptothecin - administration & dosage (16) 16
irinotecan (16) 16
leucovorin - administration & dosage (16) 16
organoplatinum compounds - administration & dosage (16) 16
original article (16) 16
retrospective studies (16) 16
cancer patients (15) 15
leucovorin (15) 15
mice (15) 15
neoplasm staging (15) 15
oxonic acid - administration & dosage (15) 15
carcinoma (14) 14
drug administration schedule (14) 14
hepatocellular carcinoma (14) 14
medicine, general & internal (14) 14
tumors (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
capecitabine (13) 13
s-1 (13) 13
adenocarcinoma - drug therapy (12) 12
apoptosis (12) 12
cells (12) 12
internal medicine (12) 12
pharmacology & pharmacy (12) 12
stomach neoplasms - mortality (12) 12
1st-line treatment (11) 11
cancer therapies (11) 11
cell line, tumor (11) 11
colorectal neoplasms - pathology (11) 11
follow-up studies (11) 11
leucovorin - adverse effects (11) 11
liver (11) 11
metastases (11) 11
nutrition & dietetics (11) 11
phase-ii (11) 11
abdominal surgery (10) 10
bevacizumab (10) 10
breast-cancer (10) 10
fluorouracil - adverse effects (10) 10
lung neoplasms - secondary (10) 10
medical research (10) 10
prospective studies (10) 10
reactive oxygen species (10) 10
colorectal neoplasms - mortality (9) 9
fluorouracil - therapeutic use (9) 9
japan - epidemiology (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Clinical Oncology, ISSN 1341-9625, 4/2015, Volume 20, Issue 2, pp. 207 - 239
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 2/2012, Volume 17, Issue 1, pp. 1 - 29
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4438 - 4444
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
Cancer Science, ISSN 1347-9032, 05/2015, Volume 106, Issue 5, pp. 627 - 634
Journal Article